Pieris Pharma

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder - President and Chief Executive Officer Hitto Kaufmann - Chief Scientific Officer Shane Olwill - Chief Development Officer Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Matt Phipps - William Blair Operator Good morning, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals Second Quarter Earnings Call. I will now turn the program over to Tom Bures, Chief Financial Officer.

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing gastric cancer patients, but Company will cease enrollment to focus its resources First-in-human regulatory submission for PRS-220 achieved, with first subject dosing planned following regulatory clearance Escalation of PRS-344/S095012 in collaboration with Servier continues AstraZeneca extends research collaboration, focusing on two discovery-stage programs with Pieris retaining co-development and U.S. co-commercialization options on both programs Strategic pipeline prioritization results in cash reach to the second quarter of 2024 BOSTON, MA / ACCESSWIRE / August 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the second quarter of 2022 ended June 30, 2022, and provided an update on the Company's recent and anticipated future developments. "AstraZeneca's deep support of PRS-060/AZD1402 and the Anticalin platform continues and has resulted in thoughtful adjustments to the PRS-060/AZD1402 phase 2a study design, allowing us to enroll patients amidst the challenges presented by COVID-19 precautions, as well as an extension of our research collaboration for two earlier-stage programs," said Stephen S.

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial (800) 285-6670 (Toll Free US & Canada) or (713) 481-1320 (International) at least five minutes prior to the start of the call.

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM EDT. A webcast of the company's presentation will be available at this link.

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT.

Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals, Inc (NASDAQ:PIRS ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Stephen S. Yoder – Chief Executive Officer, President, Director Thomas Bures – Senior Vice President, Chief Financial Officer Tim Demuth – Chief Medical Officer Conference Call Participants Jessica Hanitta Hui – Evercore ISI Roger Jiale Song – Jefferies Matthew Phipps – William Blair & Company Operator Good day and welcome to your Pieris Pharmaceuticals, Inc. First Quarter Earnings Call.

Pieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results - Earnings Call Transcript

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the first quarter of 2022 ended March 31, 2022, and provided an update on the Company's recent and anticipated future developments. "Pieris and our partners have made steady progress across the pipeline over the past quarter, and we are reiterating guidance on both cinrebafusp alfa phase 2 data in HER2-high gastric cancer in 2023 and PRS-220 clinical initiation this year.

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2022 investor call on Wednesday, May 11, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial (888) 428-7458 (Toll Free US & Canada) or (862) 298-0702 (International) at least five minutes prior to the start of the call.

Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

Shopify

Silvergate Capital Corp

Why risk-tolerant investors want to own Shopify, Silvergate Capital, and Pieris Pharmaceuticals.

3 Risky Stocks With Huge Potential Upside

Pieris Pharmaceuticals has several drugs in clinical trials, but it only takes one to make this stock a hit.

This Pharmaceutical Stock Could Be Your Lottery Ticket

Pieris Pharmaceuticals has several collaborations in place with big pharma.

This Pharmaceutical Stock Could Bank Billions Soon

Doximity

Outset Medical

Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.

3 Biotechs That Will Crush the Bear

Heron Therapeutics

Legend Biotech

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2021 Results - Earnings Call Transcript

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year Dosed first patient in phase 2 gastric study of cinrebafusp alfa; HER2-low arm data expected this year and HER2-high arm data expected in 2023 Dosed first patient in phase 1/2 solid tumor study of PRS-344/S095012 PRS-220 phase 1 initiation on track for this year Year-end cash and cash equivalents totaled $117.8 million BOSTON, MA / ACCESSWIRE / March 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the fiscal year ended December 31, 2021 and provided an update on the Company's recent and anticipated future developments. "Last year was one of steady execution as we laid the groundwork for 2022, which we believe promises to be the most important catalyst year in the Company's history, including key efficacy data for cinrebafusp alfa and PRS-060/AZD1402.

Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call.

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

Sana Biotechnology

10X Genomics

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

3 Biotechs That Will Soar Regardless of COVID-19

Leap Therapeutics

These two biotech stocks are set to report key clinical data later this year.

2 Risky Growth Stocks That Could Make You Filthy Rich

First patient has been dosed for phase 2 study using PRS-343 for treatment of patients with HER2 gastric cancer. Part 1 safety portion of the phase 2a study using PRS-060 in patients with asthma has been completed, both part 2a and part 1b have been initiated.

Pieris Is A Biotech To Watch With Extensive Pipeline And Key Partnerships

BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the first patient has been dosed in the phase 2 study of cinrebafusp alfa (PRS-343), a 4-1BB/HER2 Anticalin-based bispecific for the treatment of HER2-expressing gastric cancer. The two-arm, multicenter, open-label phase 2 study is evaluating the efficacy, safety, and tolerability of cinrebafusp alfa in combination with ramucirumab and paclitaxel in patients with HER2-high gastric cancer and in combination with tucatinib in patients with HER2-low gastric cancer.

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful completion of the sponsor safety review of part 1a of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated PRS-060/AZD1402. PRS-060/AZD1402 is an IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma.

News for Pieris Pharma Stock (PIRS)